Cinacalcet hydrochloride: Calcimimetic for the treatment of hyperparathyroidism

Expert Review of Endocrinology and Metabolism

Volumn 1, Issue 2, 2006, Pages 167-179

  Locatelli, Francesco ^a   Pontoriero, Giuseppe ^a   Limardo, Monica ^a   Tentori, Flavia ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

bone metabolism; calcimimetics; calcium sensing receptor; chronic kidney disease; cinacalcet; end stage renal disease; hyperparathyroidism; parathyroid carcinoma; vitamin D

Indexed keywords

EID: 84979964314     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/17446651.1.2.167     Document Type: Article

References (85)

1. Garcia de la Torre N, Wass JA, Turner HE. Parathyroid adenomas and cardiovascular risk. Endocrinol. Rel. Calcer. 10, 309–322 (2003).
2. 2+ -sensing receptor from bovine parathyroid. Nature 366, 575–580 (1993).
3. Brown EM. Calcium receptor and regulation of parathyroid hormone secretion. Rev. Endocrinol. Metab. Disord. 1 (4), 307–315 (2000).
4. Portale AA, Halloran PP, Morris RC Jr. Phisiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J. Clin. Invest. 83, 1494–1499 (1989).
5. Kilav R, Silver J, Naveh-Many T. Parathyroid hormone gene expression in hypophoshatemic rats. J. Clin. Invest. 96, 327–333 (1995).
6. Naveh-Many T, Rahamimov R, Livni N, Silver J. Parathyroid cell proliferation in normal and in chronic renal failure rats: the effects of calcium, phosphate and vitamin D. J. Clin. Invest. 96, 1786–1793 (1995).
7. Fukuda N, Tanaka H, Tominaga Y et al. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J. Clin. Invest. 92, 1436–1443 (1993).
8. Goodman WG, Veldhuis JD, Belin TR et al. Calcium-sensing by parathyroid gland in secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. 83, 2765–2772 (1998).
9. Locatelli F, Bommer J, London GM et al. Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. Nephrol. Dial. Transplant 16, 459–468 (2001).
10. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. 342, 1478–1483 (2000).
11. 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J. Am. Soc. Nephrol. 12, 2131–2138 (2001).
12. Block GA, Klassen P, Lazarus JM et al. Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 15, 2208–2218 (2004).
13. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcome and Practice Pattern Study. Kidney Int. 67, 1179–1187 (2005).
14. National Kidney Foundation. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 42 (S3), 1–202 (2003).
15. Young EW, Akiba T, Albert JM et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. 44 (S2), S34 –S38 (2004).
16. Locatelli F. The need for better control of secondary hyperparathyroidism. Nephrol. Dial. Transplant 19 (Suppl. 5), v15 –v19 (2004).
17. Goldsmith D, Ritz E, Covic A. Vascular calcification: a stiff challenge for the nefrologist. Kidney Int. 66, 1315–1333 (2004).
18. Chertow GM, Burke SM, Raggi P. Treat to Goal Working Group. Sevelamer attenuates the progression of coronary aortic calcification in hemodialysis patients. Kidney Int. 62, 245–252 (2002).
19. Chertow GM, Raggi P, McCarthy JT et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and ateriosclerotic vascular disease in hemodialysis patients. Am. J. Nephrol. 23, 307–314 (2003).
20. Asmus HG, Braun J, Krause R et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol. Dial. Transplant 20, 1653–1661 (2005).
21. ®): a novel, non-aluminium, non-calcium phosphate binder. Proceedings to 36th annual meeting of the American Society of Nephrology, San Diego, USA. FPO654 (2003).
22. Hutchinson AJ, Maes B, Vanwalleghem J et al. Efficacy, tolerability and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin. Pract. 100, c8 –c19 (2005).
23. De Broe M, D’Hease P (Lanthanum Study Group). Improving outcomes of hyperphosphataemia. Nephrol. Dial. Transplant 19 (Sl1), i14 –i18 (2004).
24. Lacour B, Lucas A, Auchere D et al. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int. 67 (3), 1062–1069, (2005).
25. Finn WF. No evidence for hepatotoxity after 2 years of lanthanum carbonate therapy. Proceeding of the 38th Annual Meeting of the American Society of Nephrology. Philadelphia, PA, USA SA-PO950 (2005).
26. Sprague SM, Llach F, Amdahl M et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 63, 1483–1490 (2003).
27. Malberti F, Marcelli D, Conte F, Limido A, Spotti D, Locatelli F. Parathyroidectomy in patients on renal replacement therapy: an epidemiologic study. J. Am. Soc. Nephrol. 12, 1242–1248 (2001).
28. Foley RN, Li S, Liu J et al. The fall and rise of parathyroidectomy in U.S. hemodialysis patients, 1992 to 2002. J. Am. Soc. Nephrol. 16 (1), 210–218 (2005).
29. Kinnaert P, Nagy N, Decoster-Gervy C, de Pauw L, Salmon I, Vereerstraeten P. Persistent hyperparathyroidism requiring surgical treatment after kidney transplantation. World J. Surg. 24, 1391–1395 (2000).
30. Weigel RJ. Nonoperative management of hyperparathyroidism: present and future. Curr. Opin. Oncol. 13, 33–38 (2001).
31. Chow CC, Chan WB, Li JK et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroididsm. J. Clin. Endocrinol. Metab. 88, 581–587 (2003).
32. Rubin MR, Lee KH, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 88, 1067–1178 (2003).
33. Shane E. Parathyroid carcinoma. J. Clin. Endocrinol. Metab. 86 (2), 485–493 (2001).
34. Nemeth EF. Pharmacological regulation of parathyroid hormone secretion. Curr. Pharm. Des. 8 (23), 2077–2087 (2002).
35. Nemeth EF, Heaton WH, Miller M et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J. Pharmacol. Exp. Ther. 308 (2), 627–635 (2004).
36. Nemeth EF, Steffey ME, Fox J. The parathyroid calcium receptor: a novel therapeutic target for treating hyperparathyroidism. Pediatr. Nephrol. 10(3), 275–279 (1996).
37. Goodman WG, Frazao JM, Goodkin DA et al. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int. 58, 436–445 (2000).
38. Goodman WG, Turner SA. Future role of calcimimetics in end-stage renal disease. Adv. Ren. Rep. Ther. 9 (3), 200–208 (2002).
39. Goodman WG, Hladik GA, Turner SA et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone in hemodialysis with secondary hyperparathyroidism. J. Am. Soc. Nephrol. 13, 1017–1024 (2002)
40. 2+ -sensing receptor in primary and uremic secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. 81, 1598–1606 (1996).
41. Goodman WG, Veldhuis JD, Belin TR et al. Calcium-sensing by parathyroid glands in secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. 83, 2765–2772 (1998).
42. Harris R, Padhi D, Salfi M et al. The impact of hepatic impairment on the pharmacokinetics of cinacalcet HCl. Proc. World Con. Nephrol. (Berlin) M476 (2003).
43. Padhi D, Harris R, Salfi M et al. Cinacalcet HCl absorption is not affected by coadministration of medications commonly prescribed to chronic kidney disease patients (pantoprazole sodium, sevelamer HCl, and calcium carbonate). Proceedings of 36th Annual Meeting of the American Society of Nephrology. San Diego, CA, USA, SA-P0744 (2003).
44. Harris RZ, Padhi D, Marbury TC et al. Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am. J. Kidney Dis. 44 (6), 1070–1076 (2004).
45. Padhi D, Harris R, Salfi M et al. The pharmacokinetics (PK) of cinacalcet HCl are comparable in patients with chronic kidney disease (CKD) receiving hemodialysis (HD) or chronic ambulatory peritoneal dialysis (CAPD). Proceedings of the 36th Annual Meeting of the American Society of Nephrology. San Diego, CA, USA, SA-P0745 (2003).
46. Quarles LD, Sherrard DJ, Adler S et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J. Am. Soc. Nephrol. 14 (3), 575–583 (2003).
47. Lindberg JS, Moe SM, Goodman WG et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 63 (1), 248–254 (2003).
48. Goodmann WG, Hladik GA, Turner SA et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J. Am. Soc. Nephrol. 13, 1017–1024 (2002).
49. Block GA, Coyne DW, Goodman WG et al. The calcimimetic AMG 073: a potential novel therapy for secondary hyperparathyroidism. Proceedings of the Annual Meeting of the American Society of Nephrology, Philadelphia, PA, USA. SU-PO509 (2002).
50. Cunningham J, Urena P, Reichel H et al. Long term efficacy of cinacalcet in secondary hyperparathyroidism (HPT) of end-stage renal disease (ESRD). Proceedings of the 42nd Congress of the European Renal Association and the European Dialysis and Transplant Association, Istanbul, Turkey SP210 (2005).
51. Charytan C, Coburn JW, Chonchol M et al Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am. J. Kidney Dis. 46, 58–67. (2005).
52. Chonchol M, Kopyt N, Herman J et al. Cinacalcet HCl reduces parathyroid hormone (PTH) in patients with stage 3 and 4 chronic kidney disease (CKD). Am. J. Kidney Dis. 43, 19A (2004).
53. Block GA, Martin KJ, De Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N. Engl. J. Med. 350 (15), 1516–1525 (2004).
54. Moe S, Chertow GM, Coburn JW et al. Achieving NFK-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 67, 760–771 (2005).
55. Lindberg JS, Culleton B, Wong G et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind multicenter study. J. Am. Soc. Nephrol. 16, 800–807 (2005).
56. Goodman WG, Fadda GZ, Filkelstein FO et al. Cinacalcet HCl is an effective primary therapy for the management of secondary hyperparathyroidism (HPT). Proceedings of the 36th Annual Meeting of the American Society of Nephrology. San Diego, CA, USA, SA-PO741 (2003).
57. ™ treatment targets for secondary hyperparathyroidism (HPT) in patients on dialysis. Proceedings of the 42nd Congress of the European Renal Association and the European Dialysis and Transplant Association, Istanbul, Turkey. SP209 (2005).
58. Cunningham J, Holzer H, Reichel H et al. Sustained, long-term reductions in parathyroid hormone (iPTH) after 3 years of treatment with the calcimimetic cinacalcet HCl in patients with secondary hyperparathyroidism (SHPT). Proc. World Con. Nephrol. (Berlin) M479 (2003).
59. Moe SM, Goodman WG, Cunningham J et al. Cinacalcet HCl sustains long-term control of secondary hyperparathyroidism (HPT). Proceeding of the 38th Annual Meeting of the American Society of Nephrology. Philadelphia, PA, USA F-PO755 (2005).
60. Moe SM, Cunningham J, Brommer J et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetics cinacalcet HCl. Nephrol. Dial. Transplant 20, 2168–2193 (2005).
61. Cunningham J, Danese M, Olson K et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 68, 1793–1800 (2005).
62. Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am. J. Kidney Dis. 29, 496–502 (1997).
63. Coen G, Mazzaferro S, Ballanti P et al. Renal bone disease in 76 patients with varying degrees of predialysis chronic failure: a cross-sectional study. Nephrol. Dial. Transplant 18, 813–819 (1996).
64. Spasovski GB, Bervoets AR, Behets GJ et al. Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol. Dial. Transplant 18, 1159–1166 (2003).
65. Spiegel DM, Raggi P, Mehta R et al. Coronary and aortic calcifications in patients new to dialysis. Hemodial. Int. 8 (3), 265–272 (2004).
66. Malluche HH, Monier-Faugere MC, Wang G et al. Cinacalcet HCl reduces bone turnover and bone marrow fibrosis in hemodialysis patients with secondary hyperparathyroidism (HPT). Proceedings of the 41st Congress of the European Renal Association and the European Dialysis and Transplant Association. Lisbon, M016 (2004).
67. Wada M, Furuya Y, Kobayashi N et al. The calcimimetic compound, cinacalcet HCl, ameliorated osteitis fibrosa in rats with chronic renal insufficiency. J. Bone Miner. Res. 18, s99 (2003).
68. Ishii H, Wada M, Furuya Y et al. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone 26, 175–182 (2000).
69. Lien YH, Silva AL, Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol. Dial. Transplant 20, 1232–1237 (2005).
70. Colloton M, Shatzen E, Miller G et al. Cinacalcet HCL attenuates parathyroid hyperplasia in rat model of secondary hyperparathyroidsm. Kidney Int. 67, 467–476 (2005).
71. Ogata H, Ritz E, Odoni G, Amann K, Orth SR. Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J. Am. Soc. Nephrol. 14 (4), 959–967 (2003).
72. Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol. Dial. Transplant 20, 1311–1314 (2005).
73. Serra AL, Schwarz AA, Wick FH et al. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol. Dial. Transplant 20, 1315–1319 (2005).
74. Silverberg SJ, Faiman C, Bilezikian JP et al. The effects of cinacalcet HCl (AMG 073) on serum calcium levels in patients with parathyroid carcinoma or recurrent primary hyperparathyroidism after parathyroidectomy. Proceedings of the 26th Annual Meeting of The American Society for Bone and Mineral Research. SA-420 (2003).
75. Peacock M, Bilezikian JP, Klassen PS et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 90 (1), 135–141 (2005).
76. Rothe HM, Shapiro WB, Malaton A, Chou SY. Calcium-sensing receptor gene polymorphism Arg990Gly influences the severity of secondary hyperparathyroidism (sHPT) in hemodialysis patients. Proceedings of the 38th Annual Meeting of the American Society of Nephrology. Philadelphia, PA, USA SA-PO895 (2005).
77. Rothe HM, Shapiro WB, Sun WY, Chou SY. Calcium-sensing receptor gene polymorphism Arg990Gly influences the response to a single dose of Cinacalcet HCl. Proceedings of the 38th Annual Meeting of the American Society of Nephrology. Philadelphia, PA, USA F-FC128 (2005).
78. David DS, Sakai S, Brennan BL et al. Hypercalcemia after renal transplantation. Long term follow-up data. N. Engl. J. Med. 289, 398–401 (1973).
79. Wada M, Furuya Y, Sakiyama J et al. The calcimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J. Clin. Invest. 100, 2977–2983 (1997).
80. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int. 66, 2293–2299 (2004).
81. ®) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol. Dial. Transplant 20 (7), 1370–1377 (2005).
82. Rodriguez M, Mendoza FC, Aguilera-Tejero E et al. Calcimimetic NPS R-568 decreases vascular calcification in uremic rats treated with calcitriol. Proceedings of the Annual Meeting of the American Society of Nephrology, St. Luis, Missouri F-PO983 (2004).
83. Nemeth EF, Fox J. Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends Endocrinol. Metab. 10, 66–71 (1999).
84. European Dialysis and Transplantation Association/European Renal Association (EDTA/ERA). Registry Annual Report (2001) www.era-edta.org/erafset.htm.
85. European Medicines Agency. Mimpara. European Public Assessment Reports (EPAR) www.emea.eu.int/humandocs/Humans/EPAR/mimpara/mimpara.htm.